Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the “GA transition” study
Irene Schiavetti, Pietro Annovazzi, Cinzia Cordioli, Mattia Pozzato et autres
INTRODUCTION AND OBJECTIVE: The introduction of follow-on formulations of glatiramer acetate (GA) has raised questions regarding their equivalence to the originator in real-world practice. This study aimed to evaluate the clinical effectiveness and safety of switching from originator GA to its follow-on …
it, ch (code pays fourni par la source)
0 citations
Multiple Sclerosis and Related Disorders